EW Q2 2021 Earnings — Edwards Lifesciences Corporation Revenue & Financial Results | Market Cap Arena

EWEdwards Lifesciences Corporation

$50B

Q2 2021 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$1.4B+48.8% YoY

Gross Profit

$1.1B76.3% margin

Operating Income

$451M32.7% margin

Net Income

$490M35.6% margin

EPS (Diluted)

$0.78

QoQ Revenue Growth

+13.1%

Cash Flow

Operating Cash Flow

$526M

Free Cash Flow

$457M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$7.7B

Total Liabilities

$2.5B

Stockholders' Equity

$5.1B

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.4B	$925M	+48.8%
Gross Profit	$1.1B	$679M	+54.6%
Operating Income	$451M	$221M	+103.7%
Net Income	$490M	-$122M	+501.6%

Revenue Segments

Transcatheter Heart Valves

$902M66%

Surgical Heart Valve Therapy

$237M17%

Critical Care

$215M16%

Transcatheter Mitral And Tricuspid Therapies

$22M2%

Geographic Segments

UNITED STATES

$796M58%

Europe

$310M23%

Rest of World

$139M10%

JAPAN

$132M10%